Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1981 3
1982 5
1983 6
1984 6
1985 4
1986 7
1987 9
1988 15
1989 13
1990 14
1991 8
1992 6
1993 8
1994 10
1995 9
1996 13
1997 9
1998 18
1999 17
2000 17
2001 18
2002 18
2003 14
2004 31
2005 27
2006 24
2007 42
2008 58
2009 48
2010 46
2011 66
2012 67
2013 71
2014 67
2015 69
2016 45
2017 36
2018 35
2019 18
2020 7
2021 9
2022 4
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

941 results

Results by year

Filters applied: . Clear all
Page 1
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. Among authors: gatell jm. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
The EuroSIDA study: 25 years of scientific achievements.
Laut K, Kirk O, Rockstroh J, Phillips A, Ledergerber B, Gatell J, Gazzard B, Horban A, Karpov I, Losso M, d'Arminio Monforte A, Pedersen C, Ristola M, Reiss P, Scherrer AU, de Wit S, Aho I, Rasmussen LD, Svedhem V, Wandeler G, Pradier C, Chkhartishvili N, Matulionyte R, Oprea C, Kowalska JD, Begovac J, Miró JM, Guaraldi G, Paredes R, Raben D, Podlekareva D, Peters L, Lundgren JD, Mocroft A. Laut K, et al. Among authors: gatell j. HIV Med. 2020 Feb;21(2):71-83. doi: 10.1111/hiv.12810. Epub 2019 Oct 24. HIV Med. 2020. PMID: 31647187 Free article. Review.
New challenges in therapeutic vaccines against HIV infection.
Leal L, Lucero C, Gatell JM, Gallart T, Plana M, García F. Leal L, et al. Among authors: gatell jm. Expert Rev Vaccines. 2017 Jun;16(6):587-600. doi: 10.1080/14760584.2017.1322513. Epub 2017 May 4. Expert Rev Vaccines. 2017. PMID: 28431490 Review.
Renal dysfunction in the setting of HIV/AIDS.
Miro JM, Cofan F, Trullas JC, Manzardo C, Cervera C, Tuset M, Oppenheimer F, Brunet M, Moreno A, Campistol JM, Gatell JM. Miro JM, et al. Among authors: gatell jm. Curr HIV/AIDS Rep. 2012 Sep;9(3):187-99. doi: 10.1007/s11904-012-0125-9. Curr HIV/AIDS Rep. 2012. PMID: 22706955 Review.
An Update on Heart Transplantation in Human Immunodeficiency Virus-Infected Patients.
Agüero F, Castel MA, Cocchi S, Moreno A, Mestres CA, Cervera C, Pérez-Villa F, Tuset M, Cartañà R, Manzardo C, Guaraldi G, Gatell JM, Miró JM. Agüero F, et al. Among authors: gatell jm. Am J Transplant. 2016 Jan;16(1):21-8. doi: 10.1111/ajt.13496. Epub 2015 Nov 2. Am J Transplant. 2016. PMID: 26523614 Free article. Review.
When and how to use maraviroc in HIV-infected patients.
Soriano V, Perno CF, Kaiser R, Calvez V, Gatell JM, di Perri G, Pillay D, Rockstroh J, Geretti AM. Soriano V, et al. Among authors: gatell jm. AIDS. 2009 Nov 27;23(18):2377-85. doi: 10.1097/QAD.0b013e328332d32d. AIDS. 2009. PMID: 19834318 Review. No abstract available.
Therapeutic vaccines against HIV infection.
García F, León A, Gatell JM, Plana M, Gallart T. García F, et al. Among authors: gatell jm. Hum Vaccin Immunother. 2012 May;8(5):569-81. doi: 10.4161/hv.19555. Epub 2012 May 1. Hum Vaccin Immunother. 2012. PMID: 22634436 Review.
[Position of dolutegravir in the treatment of HIV infection].
Martínez E, Gatell JM. Martínez E, et al. Among authors: gatell jm. Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:31-3. doi: 10.1016/S0213-005X(15)30007-0. Enferm Infecc Microbiol Clin. 2015. PMID: 25858610 Review. Spanish.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Among authors: gatell jm. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Clinical Trial.
941 results